Intellomx Launches Pilot Platform to Transform Early Drug Discovery
Intellomx (Intelligent OMICS Ltd) today announced the launch of Intellomx Pilot, a groundbreaking platform designed to accelerate the identification of novel drug candidates through advanced AI-driven technologies.
Building on the company’s proven expertise in precision therapeutic target identification, Intellomx Pilot introduces rapid, structure-informed hit discovery. It identifies pharmacophoric features within AI-predicted targets and performs high-throughput docking simulations across a vast chemical space of over 500 million small molecules. The system prioritizes drug-likeness, target selectivity, and reduced off-target risks to streamline hit identification and lead optimization.
Powered by Intellomx’s proprietary I³ (“Intuitive Informed Intelligence”) platform, Pilot integrates multi-omics data—including genomics, proteomics, and metabolomics—to uncover high-confidence disease-specific targets. These targets are then evaluated for druggability and cross-referenced to avoid interference with essential biological functions.
“Our I³ platform has consistently shown exceptional precision in uncovering novel disease-modifying targets,” said Professor Graham Ball, Chief Scientific Officer at Intellomx. “With Pilot, we now deliver an end-to-end AI solution that identifies both first-in-class targets and potential therapeutic molecules virtually—before any lab work begins.”
Intellomx Pilot offers pharmaceutical innovators a powerful tool to de-risk and accelerate early drug discovery, reducing time, uncertainty, and costs. This end-to-end virtual approach delivers a significant preclinical advantage, enabling faster project timelines and smarter resource allocation.
For partnership opportunities or more information, please contact:
bill.mason@intellomx.com | graham.ball@intellomx.com
Website: www.intellomx.com
About Intellomx
Intellomx (Intelligent OMICS Ltd) specializes in AI-powered biomolecular discovery and target validation, collaborating with top global pharmaceutical companies to drive smarter early-stage drug development across oncology, neurology, infectious diseases, and more.
For more details and to register, visit https://entrepreneurbulletin.com/contact-us/
Media Contact:
[Entrepreneurbulletin Business Magazine]
[pressrelease@entrepreneurbulletin.com]
[+1 6143622384 / +1 6145693002]